Oncolytic Virotherapy in Glioma Tumors.
glioblastoma
glioma
oncolytic virus
virotherapy
Journal
International journal of molecular sciences
ISSN: 1422-0067
Titre abrégé: Int J Mol Sci
Pays: Switzerland
ID NLM: 101092791
Informations de publication
Date de publication:
14 Oct 2020
14 Oct 2020
Historique:
received:
27
08
2020
revised:
08
10
2020
accepted:
12
10
2020
entrez:
17
10
2020
pubmed:
18
10
2020
medline:
26
2
2021
Statut:
epublish
Résumé
Glioma tumors are one of the most devastating cancer types. Glioblastoma is the most advanced stage with the worst prognosis. Current therapies are still unable to provide an effective cure. Recent advances in oncolytic immunotherapy have generated great expectations in the cancer therapy field. The use of oncolytic viruses (OVs) in cancer treatment is one such immune-related therapeutic alternative. OVs have a double oncolytic action by both directly destroying the cancer cells and stimulating a tumor specific immune response to return the ability of tumors to escape the control of the immune system. OVs are one promising alternative to conventional therapies in glioma tumor treatment. Several clinical trials have proven the feasibility of using some viruses to specifically infect tumors, eluding undesired toxic effects in the patient. Here, we revisited the literature to describe the main OVs proposed up to the present moment as therapeutic alternatives in order to destroy glioma cells in vitro and trigger tumor destruction in vivo. Oncolytic viruses were divided with respect to the genome in DNA and RNA viruses. Here, we highlight the results obtained in various clinical trials, which are exploring the use of these agents as an alternative where other approaches provide limited hope.
Identifiants
pubmed: 33066689
pii: ijms21207604
doi: 10.3390/ijms21207604
pmc: PMC7589679
pii:
doi:
Types de publication
Journal Article
Review
Langues
eng
Sous-ensembles de citation
IM
Subventions
Organisme : Consejería de Educación e Investigación de la Comunidad de Madrid
ID : NIETO-CM B2017/BMD-3731
Organisme : ISCIII. "Fondo de Investigaciones Sanitarias" (FIS)
ID : PI17-01489
Organisme : Miguel Servet Program
ID : CP11/00147
Références
J Natl Cancer Inst. 2006 Mar 1;98(5):298-300
pubmed: 16507823
Gene Ther. 2000 May;7(10):859-66
pubmed: 10845724
Nat Rev Drug Discov. 2019 Sep;18(9):689-706
pubmed: 31292532
Cancer Res. 2001 Dec 15;61(24):8751-7
pubmed: 11751395
PLoS One. 2013 Jun 10;8(6):e66825
pubmed: 23762498
Proc Natl Acad Sci U S A. 2001 May 22;98(11):6396-401
pubmed: 11353831
Mol Ther. 2010 Nov;18(11):1960-71
pubmed: 20808288
Hum Gene Ther. 2001 May 1;12(7):811-21
pubmed: 11339897
Mol Ther. 2004 Nov;10(5):958-66
pubmed: 15509513
Mol Ther. 2006 Jan;13(1):221-8
pubmed: 16257582
J Virol. 1998 Jun;72(6):4704-11
pubmed: 9573234
Neuro Oncol. 2020 Feb 20;22(2):301-302
pubmed: 31786602
Science. 1991 May 10;252(5007):854-6
pubmed: 1851332
Mol Ther. 2010 Jul;18(7):1275-83
pubmed: 20442708
J Neurosurg. 2004 Jun;100(6):1049-59
pubmed: 15200120
Oncolytic Virother. 2019 Oct 24;8:27-37
pubmed: 31750274
Gene Ther. 2000 May;7(10):867-74
pubmed: 10845725
Adv Ther. 2011 Apr;28(4):334-40
pubmed: 21432029
Clin Cancer Res. 2020 May 1;26(9):2216-2230
pubmed: 32019860
Biomed Res Int. 2014;2014:386470
pubmed: 25243137
Viruses. 2017 Dec 15;9(12):
pubmed: 29244745
Neurooncol Adv. 2019 May-Dec;1(1):vdz009
pubmed: 31608328
J Natl Cancer Inst. 2006 Nov 1;98(21):1546-57
pubmed: 17077357
Neurol Res. 2009 Feb;31(1):3-10
pubmed: 18937888
Future Virol. 2011 Sep;6(9):1045-1058
pubmed: 21984883
J Virol. 2004 Sep;78(17):9317-24
pubmed: 15308726
Proc Natl Acad Sci U S A. 1994 Jun 7;91(12):5247-51
pubmed: 8202476
Virol J. 2015 Jan 29;12:6
pubmed: 25630937
Nat Commun. 2018 Mar 12;9(1):1029
pubmed: 29531262
PLoS One. 2016 Jan 25;11(1):e0147211
pubmed: 26808201
J Virol. 2005 May;79(10):6005-22
pubmed: 15857987
Mol Ther Methods Clin Dev. 2020 Jan 15;17:349-358
pubmed: 32071927
J Virol. 2012 Dec;86(23):12954-70
pubmed: 22993156
Oncogene. 2000 Jan 6;19(1):2-12
pubmed: 10644974
J Natl Cancer Inst. 2007 Nov 7;99(21):1623-33
pubmed: 17971529
Cell Tissue Res. 2006 Sep;325(3):423-36
pubmed: 16699801
Cancer Res. 2004 Jul 15;64(14):4919-26
pubmed: 15256464
J Clin Invest. 1991 Dec;88(6):1924-32
pubmed: 1721625
Neurosurg Focus. 2014 Dec;37(6):E6
pubmed: 25434391
EMBO J. 1998 Jun 15;17(12):3351-62
pubmed: 9628872
Mol Ther. 2014 May;22(5):1048-55
pubmed: 24572293
Curr Gene Ther. 2005 Aug;5(4):429-43
pubmed: 16101516
J Virol. 2010 Feb;84(3):1563-73
pubmed: 19906910
Neuro Oncol. 2013 Sep;15(9):1173-85
pubmed: 23658322
J Virol. 2001 Jul;75(13):6107-14
pubmed: 11390612
J Natl Cancer Inst. 2002 Dec 4;94(23):1790-802
pubmed: 12464651
Front Oncol. 2017 Sep 08;7:195
pubmed: 28944214
Gene Ther. 2004 Nov;11(22):1648-58
pubmed: 15334111
J Virol. 2008 Jan;82(1):207-19
pubmed: 17942549
Neurohospitalist. 2014 Oct;4(4):223-9
pubmed: 25360208
Nat Rev Cancer. 2004 Jul;4(7):528-39
pubmed: 15229478
Neuro Oncol. 2010 Aug;12(8):804-14
pubmed: 20299703
Int J Cancer. 2015 Mar 1;136(5):E313-25
pubmed: 25208916
Nat Med. 1995 Sep;1(9):938-43
pubmed: 7585221
Viral Immunol. 2002;15(2):229-46
pubmed: 12081009
Mol Ther. 2008 Mar;16(3):627-32
pubmed: 18253152
Cancer Gene Ther. 2010 Apr;17(4):244-55
pubmed: 19798121
Proc Natl Acad Sci U S A. 1996 Mar 19;93(6):2370-5
pubmed: 8637880
Cancer Res. 2005 Nov 1;65(21):9982-9990
pubmed: 16267023
Oncol Res. 1999;11(3):133-44
pubmed: 10527073
Mol Ther. 2015 Jan;23(1):108-18
pubmed: 25352242
Front Oncol. 2020 Apr 16;10:475
pubmed: 32373515
Mol Ther. 2012 May;20(5):994-1001
pubmed: 22354378
Cell Adh Migr. 2008 Jul-Sep;2(3):208-13
pubmed: 19262110
Oncolytic Virother. 2015 Aug 27;4:109-18
pubmed: 27512675
Virology. 1993 Nov;197(1):405-11
pubmed: 8212574
J Neurooncol. 2009 Nov;95(2):199-209
pubmed: 19521665
J Immunother. 2001 Jan-Feb;24(1):46-57
pubmed: 11211148
J Virol. 2007 Apr;81(8):4186-98
pubmed: 17287256
Mol Ther. 2010 Feb;18(2):285-94
pubmed: 19844198
Cancer Cell. 2003 Oct;4(4):263-75
pubmed: 14585354
Front Oncol. 2014 Jun 11;4:145
pubmed: 24967214
J Clin Oncol. 2004 Nov 1;22(21):4272-81
pubmed: 15452186
Virology. 2006 Dec 5-20;356(1-2):155-64
pubmed: 16945399
Oncotarget. 2017 Mar 14;8(11):18031-18049
pubmed: 28160553
Mol Ther. 2014 May;22(5):1056-62
pubmed: 24553100
Mol Ther Methods Clin Dev. 2020 Mar 30;17:871-893
pubmed: 32373649
Int J Mol Med. 2015 Jul;36(1):3-10
pubmed: 25998621
J Oncol. 2019 Jul 29;2019:1740763
pubmed: 31467533
Virus Res. 2014 May 12;184:71-81
pubmed: 24589707
Cancer Res. 2007 Sep 1;67(17):8255-63
pubmed: 17804740
Mol Ther. 2007 Apr;15(4):651-9
pubmed: 17299401
Cancer J. 2012 Jan-Feb;18(1):69-81
pubmed: 22290260
Gene Ther. 2009 Dec;16(12):1441-51
pubmed: 19710704
Nat Immunol. 2004 Dec;5(12):1266-74
pubmed: 15502830
Science. 1996 Oct 18;274(5286):373-6
pubmed: 8832876
Sci Rep. 2018 Jul 31;8(1):11470
pubmed: 30065314
Cancer Gene Ther. 2000 Nov;7(11):1437-47
pubmed: 11129286
Cancer Res. 2013 Jan 15;73(2):865-74
pubmed: 23293278
Adv Virus Res. 2007;69:1-66
pubmed: 17222691
Clin Cancer Res. 2009 Apr 15;15(8):2777-88
pubmed: 19351762
Hum Gene Ther. 2012 Apr;23(4):419-27
pubmed: 22185260
Gene Ther. 1998 Jan;5(1):121-30
pubmed: 9536273
Crit Rev Oncol Hematol. 2000 Nov-Dec;36(2-3):193-207
pubmed: 11033306
Mol Ther. 2008 Nov;16(11):1865-72
pubmed: 18766173
Neuro Oncol. 2016 Mar 8;18(8):1088-1098
pubmed: 26962017
Neuro Oncol. 2019 Nov 1;21(Suppl 5):v1-v100
pubmed: 31675094
Neuro Oncol. 2004 Jul;6(3):208-17
pubmed: 15279713
Mol Ther. 2007 Apr;15(4):677-86
pubmed: 17299404
Cancer Res. 2002 Feb 1;62(3):764-72
pubmed: 11830531
Virus Res. 2009 Aug;143(2):184-94
pubmed: 19647886
Clin Cancer Res. 2019 Jan 1;25(1):290-299
pubmed: 30279232
Mol Ther. 2010 Feb;18(2):377-85
pubmed: 19904233
Oncogene. 2010 Apr 15;29(15):2205-16
pubmed: 20101224
BMC Cancer. 2012 Mar 21;12:99
pubmed: 22436661
J Virol. 2009 Nov;83(22):11540-9
pubmed: 19726512
J Egypt Natl Canc Inst. 2016 Dec;28(4):199-210
pubmed: 27476474
Stem Cell Res Ther. 2016 Oct 10;7(1):149
pubmed: 27724977
Cancers (Basel). 2019 Feb 05;11(2):
pubmed: 30764570
J Virol. 2012 Jul;86(13):7280-91
pubmed: 22553327
J Virol. 1998 Sep;72(9):7064-74
pubmed: 9696799
Nat Biotechnol. 2004 Jan;22(1):70-7
pubmed: 14647305
Cancer Res. 2005 Apr 1;65(7):2832-9
pubmed: 15805284
Mol Ther. 2017 Dec 6;25(12):2620-2634
pubmed: 28967558
Nat Biotechnol. 1997 Jun;15(6):542-6
pubmed: 9181576
Sci Transl Med. 2018 Jan 3;10(422):
pubmed: 29298869
Clin Cancer Res. 2001 Jan;7(1):120-6
pubmed: 11205899
J Biomed Biotechnol. 2010;2010:350748
pubmed: 20224643
Int J Mol Sci. 2020 May 21;21(10):
pubmed: 32455640
J Virol. 2004 Jul;78(13):6709-14
pubmed: 15194745
J Natl Cancer Inst. 2001 Jun 20;93(12):903-12
pubmed: 11416111
Oncolytic Virother. 2018 Nov 19;7:107-116
pubmed: 30538967
Virology. 2015 Jan 15;475:1-14
pubmed: 25462341
Cancer Res. 2003 May 15;63(10):2462-9
pubmed: 12750267
Cancer Res. 2017 Jul 15;77(14):3894-3907
pubmed: 28566332
J Virol. 1992 Aug;66(8):4992-5001
pubmed: 1385835
Cells. 2020 Jun 05;9(6):
pubmed: 32516884
IUBMB Life. 2000 Aug;50(2):135-8
pubmed: 11185959
Mol Ther. 2009 Jan;17(1):199-207
pubmed: 18957964
J Virol. 2001 Dec;75(23):11573-82
pubmed: 11689639
Cancer Gene Ther. 2018 Jun;25(5-6):106-116
pubmed: 29755109
J Virol. 2006 Jun;80(11):5145-55
pubmed: 16698995
Neuron. 2002 Nov 14;36(4):555-8
pubmed: 12441045
J Clin Oncol. 2018 May 10;36(14):1419-1427
pubmed: 29432077
JAMA. 2017 Dec 19;318(23):2306-2316
pubmed: 29260225
Proc Natl Acad Sci U S A. 2006 Aug 22;103(34):12873-8
pubmed: 16908838
Adv Virus Res. 2007;70:183-232
pubmed: 17765706
Pediatr Blood Cancer. 2010 Aug;55(2):295-303
pubmed: 20582972
J Virol. 1999 Sep;73(9):7556-64
pubmed: 10438845
Acta Neuropathol. 2016 Jun;131(6):803-20
pubmed: 27157931
J Gen Virol. 2000 Nov;81(Pt 11):2683-2688
pubmed: 11038380
Br J Cancer. 1996 Sep;74(5):745-52
pubmed: 8795577
Mol Ther Oncolytics. 2019 Nov 02;15:234-247
pubmed: 31872046
N Engl J Med. 2018 Jul 12;379(2):150-161
pubmed: 29943666
Nat Rev Drug Discov. 2019 Jul;18(7):553-566
pubmed: 30967658
Curr Treat Options Oncol. 2019 Feb 21;20(3):24
pubmed: 30790064
Transl Oncol. 2018 Feb;11(1):86-93
pubmed: 29216507
J Neurosci. 2008 Feb 20;28(8):1882-93
pubmed: 18287505
Neuro Oncol. 2005 Jul;7(3):213-24
pubmed: 16053696
Pharmacol Rev. 2018 Jul;70(3):412-445
pubmed: 29669750
Clin Cancer Res. 2018 Jun 1;24(11):2574-2584
pubmed: 29511029
N Engl J Med. 2005 Mar 10;352(10):987-96
pubmed: 15758009
J Virol Methods. 2009 Jan;155(1):44-54
pubmed: 18951922
Immunotherapy. 2015;7(12):1249-58
pubmed: 26595180
Proc Natl Acad Sci U S A. 2000 Jun 6;97(12):6803-8
pubmed: 10841575
J Neurooncol. 2004 Mar-Apr;67(1-2):83-93
pubmed: 15072452
Hum Gene Ther. 2006 Jan;17(1):31-45
pubmed: 16409123
J Gene Med. 2004 Oct;6(10):1082-91
pubmed: 15368589
Gene Ther. 2007 Jul;14(13):1045-54
pubmed: 17429445